Alps Group Completes $1.6 Billion SPAC Merger, Lists on Nasdaq to Advance Precision Medicine Platform
核心洞察
Alps Group Inc (搜索) successfully completed its business combination with Globalink Investment Inc (搜索), creating a publicly traded biotechnology company with an estimated enterprise value of approximately $1.6 billion.
The combined company began trading on Nasdaq under the ticker symbol "ALPS" on October 31, 2025, positioning the Malaysian-headquartered firm on a global platform to advance its precision medicine initiatives.
Alps Group operates as an integrated biotechnology platform specializing in predictive, preventive, and precision medicine, with focus areas including next-generation mRNA (搜索), personalized vaccines (搜索), and cellular therapies (搜索).
Alps Group Inc (搜索) successfully completed its business combination with special purpose acquisition company Globalink Investment Inc (搜索) on October 31, 2025, creating a publicly traded biotechnology platform valued at approximately $1.6 billion. The Malaysian-headquartered company began trading on the Nasdaq Stock Market under the ticker symbol "ALPS" the same day, marking a significant milestone in its mission to advance predictive, preventive, and precision medicine globally.
Transaction Structure and Financial Details
The business combination was executed through a two-step merger process approved by Globalink's stockholders on October 7, 2025. The transaction involved a redomestication merger where Globalink merged into Alps Group, followed by an acquisition merger that made Alps Life Sciences Inc (搜索). a wholly owned subsidiary of the combined entity.
In conjunction with the merger, Alps Group secured approximately $3.1 million through a PIPE (private investment in public equity) investment from institutional investors, representing approximately 310,788 ordinary shares. These funds will support the company's growth strategy and working capital requirements as it expands its biotechnology platform.
Leadership and Strategic Vision
Dr. Tham Seng Kong will serve as Chief Executive Officer and Chairman of Alps Group's Board of Directors following the transaction's completion. The company will maintain its headquarters in Kuala Lumpur, Malaysia, while leveraging its new Nasdaq listing to expand its global reach.
"Today marks a definitive milestone for ALPS as we join Nasdaq's global stage," stated Dr. Tham. "What began as a lifelong passion in genomics and cellular research has evolved into a mission to redefine the future of healthcare. From decoding the human genome to developing next-generation mRNA (搜索) and personalized vaccines (搜索) together with cellular therapies (搜索), our mission has always been to deliver predictive, preventive, and precision medicine to patients worldwide — at a cost that makes life-saving care accessible to all."
Biotechnology Platform and Research Focus
Alps Group operates as an integrated biotechnology platform that combines research and development, medical services, and wellness solutions under a unified ecosystem. The company's core mission centers on creating accessible and affordable advanced healthcare solutions through predictive, preventive, and precision medicine approaches.
The company's research portfolio encompasses genomics, cellular research, next-generation mRNA (搜索) technologies, personalized vaccines (搜索), and cellular therapies (搜索). This comprehensive approach positions Alps Group to address multiple therapeutic areas while maintaining focus on making life-saving treatments accessible to patients worldwide.
BioValley Initiative and Global Expansion
The Nasdaq listing will accelerate development of Alps Group's BioValley initiative, described as a cutting-edge biotechnology hub designed to foster collaborative ecosystems for innovators, investors, scientific talent, and patients globally. This initiative represents the company's strategy to demonstrate Malaysia's capacity to incubate high-technology companies capable of competing on an international scale.
"Our Nasdaq listing establishes ALPS on a global platform amplifying our brand, expanding our reach and, will also accelerate the development of our BioValley initiative," Dr. Tham explained. "We are committed to bridging gaps in the biotech industry fostering collaboration across research, manufacturing, and clinical applications, both regionally and globally."
Market Position and Future Outlook
The successful completion of this business combination positions Alps Group as a significant player in the precision medicine sector, with access to U.S. capital markets and enhanced visibility among institutional investors. The company's warrants will trade on the Over-the-Counter Market under the symbol "ALPWF."
Say Leong Lim, former CEO and Chairman of Globalink, noted the transaction's significance for shareholders: "We are pleased to have successfully consummated the Business Combination, marking the beginning of a new chapter for Globalink's stockholders and the future growth potential of the Company."
The merger agreement, originally executed in January 2024 and subsequently amended multiple times through September 2025, reflects the complex nature of cross-border biotechnology transactions and the companies' commitment to completing the strategic combination despite regulatory and market challenges.